Press Releases

Press Releases

    Date Title View
    02/23/22
    Summary ToggleHorizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)
    PDF Version
    02/21/22
    Summary ToggleHorizon Therapeutics plc to Present at the Cowen and Company 42nd Annual Health Care Conference
    PDF Version
    02/16/22
    Summary ToggleHorizon Therapeutics plc Names Sean Clayton Executive Vice President and General Counsel
    PDF Version
    02/16/22
    Summary ToggleNew Analysis Demonstrates UPLIZNA® (inebilizumab-cdon) Reduces Severity of Attacks Associated with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    02/15/22
    Summary ToggleNew Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA® (teprotumumab-trbw) Comparable with Clinical Trial Observations
    PDF Version
    02/15/22
    Summary ToggleHorizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
    PDF Version
    02/10/22
    Summary ToggleHorizon Therapeutics plc Named Title Partner of the Irish Open
    PDF Version
    02/07/22
    Summary ToggleHorizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2021 Financial Results and Host Webcast on March 1, 2022
    PDF Version
    01/24/22
    Summary ToggleHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
    PDF Version
    01/10/22
    Summary ToggleHorizon Therapeutics plc Submits Supplemental Biologics License for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living with Uncontrolled Gout
    PDF Version
    Displaying 21 - 30 of 655 results